- Home
- BIIB vs KEY Comparison
BIIB vs KEY Comparison
Compare BIIB & KEY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- KEY
- Stock Information
- Founded
- BIIB 1978
- KEY 1825
- Country
- BIIB United States
- KEY United States
- Employees
- BIIB N/A
- KEY N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- KEY Major Banks
- Sector
- BIIB Health Care
- KEY Finance
- Exchange
- BIIB Nasdaq
- KEY Nasdaq
- Market Cap
- BIIB 22.2B
- KEY 18.5B
- IPO Year
- BIIB 1991
- KEY N/A
- Fundamental
- Price
- BIIB $143.06
- KEY $17.49
- Analyst Decision
- BIIB Buy
- KEY Buy
- Analyst Count
- BIIB 26
- KEY 18
- Target Price
- BIIB $234.79
- KEY $19.31
- AVG Volume (30 Days)
- BIIB 1.4M
- KEY 10.4M
- Earning Date
- BIIB 02-11-2025
- KEY 01-21-2025
- Dividend Yield
- BIIB N/A
- KEY 4.69%
- EPS Growth
- BIIB 10.05
- KEY N/A
- EPS
- BIIB 11.06
- KEY 0.00
- Revenue
- BIIB $9,607,500,000.00
- KEY $4,852,000,000.00
- Revenue This Year
- BIIB N/A
- KEY N/A
- Revenue Next Year
- BIIB N/A
- KEY $25.38
- P/E Ratio
- BIIB $13.58
- KEY $7,051.23
- Revenue Growth
- BIIB N/A
- KEY N/A
- 52 Week Low
- BIIB $142.42
- KEY $12.94
- 52 Week High
- BIIB $252.17
- KEY $20.04
- Technical
- Relative Strength Index (RSI)
- BIIB 31.71
- KEY 49.06
- Support Level
- BIIB $149.73
- KEY $16.55
- Resistance Level
- BIIB $150.48
- KEY $17.69
- Average True Range (ATR)
- BIIB 3.56
- KEY 0.38
- MACD
- BIIB 0.18
- KEY 0.04
- Stochastic Oscillator
- BIIB 4.59
- KEY 82.02
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About KEY KeyCorp
With assets of over $180 billion, Ohio-based KeyCorp's bank footprint spans 16 states, but it is predominantly concentrated in its two largest markets: Ohio and New York. KeyCorp is primarily focused on serving middle-market commercial clients through a hybrid community/corporate bank model.